Systemic Absorption of Cyclopentolate and Adverse Events After Retinopathy of Prematurity Exams

References

• Hamilton BE, Hoyert DL, Martin JA, Strobino DM, Guyer B. Annual summary of vital statistics: 2010–2011. Pediatrics 2013;131(3):548–558.
   PubMed Web of Science ®Google Scholar
• Harrell SN, Brandon DH. Retinopathy of prematurity: the disease process, classifications, screening, treatment, and outcomes. Neonatal Netw 2007;26(6):371–8.
   PubMedGoogle Scholar
• Fierson WM, Screening examination of premature infants for retinopathy of prematurity. Pediatrics 2013;131(1):189–95.
   PubMed Web of Science ®Google Scholar
• Neffendorf JE, Mota PM, Xue K, Hildebrand GD. Efficacy and safety of phenylephrine 2.5% with cyclopentolate 0.5% for retinopathy of prematurity screening in 1246 eye examinations. Eur J Ophthalmol 2015;25(3):249–253.
   PubMed Web of Science ®Google Scholar
• Ishikawa H, DeSantis L, Patil PN. Selectivity of muscarinic agonists including (+/−)-aceclidine and antimuscarinics on the human intraocular muscles. J Ocul Pharmacol Ther 1998;14(4):363–373.
   PubMed Web of Science ®Google Scholar
• Ford AP, Daniels DV, Chang DJ, Gever JR, Jasper JR, Lesnick JD, et al. Pharmacological pleiotropism of the human recombinant alpha1A-adrenoceptor: implications for alpha1-adrenoceptor classification. Br J Pharmacol 1997;121(6):1127–1135.
   PubMed Web of Science ®Google Scholar
• Taniguchi T, Inagaki R, Murata S, Akiba I, Muramatsu I. Microphysiometric analysis of human alpha1a-adrenoceptor expressed in Chinese hamster ovary cells. Br J Pharmacol 1999;127(4):962–968.
   PubMed Web of Science ®Google Scholar
• Minneman KP, Theroux TL, Hollinger S, Han C, Esbenshade TA. Selectivity of agonists for cloned alpha 1-adrenergic receptor subtypes. Mol Pharmacol 1994;46(5):929–936.
   PubMed Web of Science ®Google Scholar
• Laws DE, Morton C, Weindling M, Clark D. Systemic effects of screening for retinopathy of prematurity. Eur J Ophthalmol 1996;80(5):425–428.
   Google Scholar
• Rush R, Rush S, Nicolau J, Chapman K, Naqvi M. Systemic manifestations in response to mydriasis and physical examination during screening for retinopathy of prematurity. Retina 2004;24(2):242–245.
   PubMed Web of Science ®Google Scholar
• Derinoz O, Emeksiz HC. Use of physostigmine for cyclopentolate overdose in an infant. Pediatrics 2012;130(3):e703–e705.
   Google Scholar
• Young TE. Pharmacology review: topical mydriatics: the adverse effects of screening examinations for retinopathy of prematurity. Neoreviews 2003;4(6):e163–e166.
   Google Scholar
• Pooniya V, Pandey N. Systemic toxicity of topical cyclopentolate eyedrops in a child. Eye 2012;26(10):1391–1392.
   PubMed Web of Science ®Google Scholar
• Princelle A, Hue V, Pruvost I, Potey C, Dubos F, Martinot A. [Systemic adverse effects of topical ocular instillation of atropine in two children]. Arch Pediatrie. 2013;20(4):391–4.
   PubMed Web of Science ®Google Scholar
• Ozgun U, Demet T, Ozge KA, Zafer D, Murat S, Mehmet Y, et al. Fatal necrotising enterocolitis due to mydriatic eye drops. J Coll Physicians Surg Pak. 2014;24 Suppl 2:S147–S149.
   Google Scholar
• Mitchell AJ, Green A, Jeffs DA, Roberson PK. Physiologic effects of retinopathy of prematurity screening examinations. Adv Neonatal Care 2011;11(4):291–297.
   PubMedGoogle Scholar
• Leeder JS, Kearns GL. Interpreting pharmacogenetic data in the developing neonate: the challenge of hitting a moving target. Clin Pharmacol Ther 2012;92(4):434–436.
   PubMed Web of Science ®Google Scholar
• Sage DP, Kulczar C, Roth W, Liu W, Knipp GT. Persistent pharmacokinetic challenges to pediatric drug development. Front Genet 2014;5:1–8.
   Google Scholar
• Lahdes K, Huupponen R, Kaila T, Monti D, Saettone MF, Salminen L. Plasma concentrations and ocular effects of cyclopentolate after ocular application of three formulations. Br J Clin Pharmacol 1993;35(5):479–483.
   PubMed Web of Science ®Google Scholar
• Mollerup HM, Gatke MR. Butyrylcholinesterase gene mutations in patients with prolonged apnea after succinylcholine for electroconvulsive therapy. Acta Anaesthesiol Scand 2011;55(1):82–86.
   PubMed Web of Science ®Google Scholar
• Lee JM, Kodsi SR, Gaffar MA, Rubin SE. Cardiopulmonary arrest following administration of Cyclomydril eyedrops for outpatient retinopathy of prematurity screening. J AAPOS 2014;18(2):183–184.
   PubMed Web of Science ®Google Scholar
• Wood MG, Kaufman LM. Apnea and bradycardia in two premature infants during routine outpatient retinopathy of prematurity screening. J AAPOS. 2009;13(5):501–503.
   PubMed Web of Science ®Google Scholar
• Bates JH, Burnstine RA. Consequences of retinopathy of prematurity examinations. Case report. Arch Ophthalmol 1987;105(5):618–619.
   PubMedGoogle Scholar
• Hermansen MC, Sullivan LS. Feeding intolerance following ophthalmologic examination. Am J Dis Child 1985;139(4):367–368.
   PubMedGoogle Scholar
• Haaga M, Kaila T, Salminen L, Ylitalo P. Systemic and ocular absorption and antagonist activity of topically applied cyclopentolate in man. Pharmacol Toxicol 1998;82(1):19–22.
   PubMedGoogle Scholar
• Lahdes K, Huupponen R, Kaila T, Ali-Melkkila T, Salminen L, Saari M. Systemic absorption of ocular cyclopentolate in children. Ger J Ophthalmol 1992;1(1):16–18.
   PubMedGoogle Scholar
• Hengstmann JH, Goronzy J. Pharmacokinetics of 3H-phenylephrine in man. Eur J Clin Pharmacol 1982;21(4):335–341.
   PubMed Web of Science ®Google Scholar
• Lu H, Rosenbaum S. Developmental pharmacokinetics in pediatric populations. J Pediatr Pharmacol Ther 2014;19(4):262–276.
   PubMedGoogle Scholar
• Alcorn J, McNamara PJ. Pharmacokinetics in the newborn. Adv Drug Deliv Rev 2003;55(5):667–686.
   PubMed Web of Science ®Google Scholar
• Ohashi T, Kase M, Yokoi M. Quantitative analysis of the oculocardiac reflex by traction on human extraocular muscle. Invest Ophthalmol Vis Sci 1986;27(7):1160–1164.
   PubMed Web of Science ®Google Scholar
• Wellstein A, Pitschner HF. Complex dose-response curves of atropine in man explained by different functions of M1- and M2-cholinoceptors. Naunyn Schmiedebergs Arch Pharmacol 1988;338(1):19–27.
   PubMed Web of Science ®Google Scholar
• Bharucha AE, Ravi K, Zinsmeister AR. Comparison of selective M3 and nonselective muscarinic receptor antagonists on gastrointestinal transit and bowel habits in humans. Am J Physiol Gastrointest Liver Physiol 2010;299(1):G215–G219.
   Google Scholar
• Moulton BC, Fryer AD. Muscarinic receptor antagonists, from folklore to pharmacology; finding drugs that actually work in asthma and COPD. Br J Pharmacol 2011;163(1):44–52.
   PubMed Web of Science ®Google Scholar
• Silvestri JM. Indications for home apnea monitoring (or not). Clin Perinatol 2009;36(1):87–99.
   PubMed Web of Science ®Google Scholar
• Bonthala S, Sparks JW, Musgrove KH, Berseth CL. Mydriatics slow gastric emptying in preterm infants. J Pediatr 2000;137(3):327–330.
   PubMed Web of Science ®Google Scholar
• Lim DL, Batilando M, Rajadurai VS. Transient paralytic ileus following the use of cyclopentolate-phenylephrine eye drops during screening for retinopathy of prematurity. J Paediatr Child Health 2003;39(4):318–320.
   PubMed Web of Science ®Google Scholar
• Rozette NA, Matragoon S, Sethi S, Goei S, Manasco KB, El-Remessy AB. Systemic effects of ophthalmic cyclopentolate on body weight in neonatal mice. Neonatology 2014;106(1):37–41.
   PubMed Web of Science ®Google Scholar
• Vicente GV, Bahri M, Palafoutas JJ, Wang H, Mehta N. A randomized controlled trial to determine the lowest effective dose for adequate mydriasis in premature infants. J AAPOS 2012;16(4):365–369.
   PubMed Web of Science ®Google Scholar
• Fanni D, Ambu R, Gerosa C, Nemolato S, Castagnola M, Van Eyken P, et al. Cytochrome P450 genetic polymorphism in neonatal drug metabolism: role and practical consequences towards a new drug culture in neonatology. Int J Immunopathol Pharmacol 2014;27(1):5–13.
   PubMed Web of Science ®Google Scholar
• Bretlau C, Sorensen MK, Vedersoe AL, Rasmussen LS, Gatke MR. Response to succinylcholine in patients carrying the K-variant of the butyrylcholinesterase gene. Anesth Analg 2013;116(3):596–601.
   PubMed Web of Science ®Google Scholar
• Parnas ML, Procter M, Schwarz MA, Mao R, Grenache DG. Concordance of butyrylcholinesterase phenotype with genotype: implications for biochemical reporting. Am J Clin Pathol 2011;135(2):271–276.
   PubMed Web of Science ®Google Scholar
• Donfack J, Kogut P, Forsythe S, Solway J, Ober C. Sequence variation in the promoter region of the cholinergic receptor muscarinic 3 gene and asthma and atopy. J Allergy Clin Immunol 2003;111(3):527–532.
   PubMed Web of Science ®Google Scholar
• Weber S, Thiele H, Mir S, Toliat MR, Sozeri B, Reutter H, et al. Muscarinic acetylcholine receptor M3 mutation causes urinary bladder disease and a Prune-Belly-like Syndrome. Am J Hum Genet 2011;89(5):668–674.
   PubMed Web of Science ®Google Scholar